Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

Apeiron Biologics AG. (1/9/14). "Press Release: Apeiron Signs Regional License Agreements for the Commercialization of Its Neuroblastoma Therapy". Vienna.

Region Region Israel
Organisations Organisation Apeiron Biologics AG
  Group Apeiron (Group)
  Organisation 2 Medison Pharma Ltd.
  Today Midven Ltd.
Products Product APN311 (Apeiron)
  Product 2 cancer immunotherapy (immuno-oncology, I-O)
Index terms Index term Medison Pharma–Apeiron: APN311, 201401– license €na excl rights to market + sell APN311 in Israel
  Index term 2 Gen Ilac–Apeiron: APN311, 201401– license €na excl rights to market + sell APN311 in Turkey
Persons Person Loibner, Hans (Apeiron Biologics 200810–201807 CEO RETIRED 7/18 continues as senior advisor)
  Person 2 Jakobsohn, Meir (Medison Pharma 201401 CEO + Founder)
     


APEIRON Biologics AG ('Apeiron') today announced the signing of two transactions as part of the worldwide commercialization of APN311, an antibody-based immunotherapy in development for the treatment of children suffering from high-risk neuroblastoma. Medison Pharma ('Medison'), Israel's leading marketing group for innovative niche healthcare solutions, and Gen Ilaç ve Saglik Ürünleri ('Gen Ilac'), a leading supplier of orphan drugs for the treatment of rare diseases in Turkey, entered into license agreements with Apeiron, under the terms of which they receive the exclusive rights to market and sell APN311 in Israel and Turkey, respectively.

Today Apeiron announced the signing of license agreements with Medison and Gen Ilac. The two deals grant Medison and Gen Ilac exclusive rights to market and sell APN311 in Israel and Turkey, respectively. These transactions are part of Apeiron's ongoing activities for worldwide commercialization of its immunotherapy portfolio against high-risk neuroblastoma. APN311 is the most advanced biologic in Apeiron's development pipeline that focuses on immunologic therapies of cancer. Further details or financial terms of the transaction were not disclosed.

Hans Loibner, PhD, CEO of Apeiron, commented, 'Based on very positive clinical data and the advanced development status of APN311 we are actively engaged in discussions with potential partners around the world for commercialization of this immunotherapy. After a first agreement with Paladin Labs we are pleased to now close these two deals with Medison and Gen Ilac. This represents a further important step in Apeiron's efforts and commitment to improve therapeutic options for children suffering from life-threatening high-risk neuroblastoma.'

Meir Jakobsohn, Medison's Founder & CEO, commented, 'We are proud of the new agreement with Apeiron that reflects Medison's continuous ambition to provide breakthrough and lifesaving treatments for today's most urgent medical needs. One of Medison's main focuses is providing medications in the field of pediatric oncology, in niches with unmet need. Apeiron's treatment fits exactly to Medison's mission.'

Abidin Gülmüs, CEO of Gen Ilac, added, 'We are proud of our reputation as one of Turkey's leading specialty pharma companies, but even more important to us is the difference we make to the lives of people with life-threatening conditions. We look forward to a successful partnership with Apeiron, together providing oncologists with the opportunity to treat high-risk neuroblastoma patients. We aspire to make APN311 available for Turkish patients as soon as possible.'


About Neuroblastoma and APN311

Neuroblastoma is the most common extracranial solid cancer in infants and children with 50% of all cases being diagnosed within the first year after birth.

APN311 is a monoclonal chimeric antibody (ch14.18/CHO) targeting the GD2 antigen on neuroblastoma cells and is currently in preparation for submission for marketing authorization.


About APEIRON Biologics AG (as of January 2014)

Apeiron is a mainly privately financed biotech company based in Vienna, Austria, developing immunologic and biologic therapies against cancer. Its portfolio consists of five clinical projects and some preclinical approaches. Its lead project, APN311, is currently being investigated in high-risk neuroblastoma, together with the internationally active SIOPEN study group, with more than 600 patients having received treatment to date. Apeiron's project APN301 is an anti-GD2 antibody-IL2 fusion protein which is currently in a phase II trial in the US and Canada in neuroblastoma and in a separate trial in melanoma. The recombinant human Angiotensin Converting Enzyme 2 (GSK2586881, formerly APN01) was developed by Apeiron until end of Phase I, licensed to GlaxoSmithKline (GSK) in 2010 and is presently being investigated by GSK in an ongoing phase II study in Acute Lung Injury. Furthermore, a program is ongoing to develop therapies to selectively boost the immune system to efficiently combat cancer (APN401: individualized cellular therapy; APN411: low molecular weight compound, in collaboration with Evotec). APN201 (human Superoxide Dismutase) is pursued to cope with oxidative stress and associated inflammation.

Apeiron was supported by Dechert, Eisei GmbH and JSB Partners in this transaction.

www.apeiron-biologics.com


About Medison Pharma

Medison is Israel's leading marketing group, representing innovative niche healthcare products from companies such as Biogen, Amgen, Shire and Ipsen. Medison strives to deliver the most innovative healthcare solutions to patients. The company operates according to a comprehensive approach to marketing and service, and maintains long-standing relations with HMOs (Health Maintenance Organizations), local medical centers and physicians. Backed by three generations of experience in the healthcare industry since 1937, Medison is uniquely qualified to provide the complete spectrum of integrated services for international companies looking to enter into or expand their presence in the Israeli & Romanian healthcare markets.

Medison has offices and is active in Israel and Romania.
www.medison.co.il


About Gen Ilac

Gen Ilac is a leading specialty pharmaceutical company headquartered in Ankara, Turkey, and represents innovative pharmaceutical and biotechnology companies, serving the medical community and patients in specific therapeutic areas of Neurology, Oncology, Hematology, Endocrinology and Nephrology. The company has long term collaborations with a number of international companies including Biogen Idec, Ipsen, Onyx, Gentium and many others. Gen Ilac is taking a leading role in Turkey bringing novel treatment options to patients with difficult to treat or rare conditions.
www.genilac.com.tr


Contact Apeiron:

Dr. Hans Loibner, CEO
Campus-Vienna-Biocenter 5
1030 Vienna, Austria
+43 1 865 65 77
apeiron@apeiron-biologics.com
www.apeiron-biologics.com

   
Record changed: 2017-04-02

Advertisement

Picture [iito] – Putting Information into Context 600x102px

More documents for Apeiron (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px




» top